Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient Mice

Blood

Volumn 118, Issue 7, 2011, Pages 1998-2006

  Cheng, Zhongjian ^a   Jiang, Xiaohua ^a   Kruger, Warren D ^b   Praticò, Domenico ^a   Gupta, Sapna ^b   Mallilankaraman, Karthik ^a   Madesh, Muniswamy ^a   Schafer, Andrew I ^c   Durante, William ^d   Yang, Xiaofeng ^a   Wang, Hong ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIOXIDANT; CALCIUM ACTIVATED POTASSIUM CHANNEL; CATALASE; CYSTATHIONINE BETA SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HOMOCYSTEINE; IK1 PROTEIN; MEMBRANE PROTEIN; NITRIC OXIDE; PEROXYNITRITE; SK3 PROTEIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME DEFICIENCY; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; MESENTERIC ARTERY; MICROVASCULATURE; MOUSE; NITRATION; NONHUMAN; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; TISSUE LEVEL; TRANSGENIC MOUSE; VASODILATATION;

EID: 80051915426     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-333310     Document Type: Article

References (38)

1. Jiang X., Yang F., Tan H., et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol. 2005;25(12):2515-2521. (Pubitemid 43732272)
2. Virdis A., Iglarz M., Neves M.F., et al. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(8):1352-1357. (Pubitemid 36994521)
3. De Vriese A.S., Blom H.J., Heil S.G., et al. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation. 2004;109(19):2331-2336. (Pubitemid 38656870)
4. Cheng Z., Yang X., Wang H. Hyperhomocysteinemia and Endothelial Dysfunction. Curr Hypertens Rev. 2009;5(2):158-165.
5. Chao C.L., Kuo T.L., Lee Y.T. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000;101(5):485-490.
6. Kanani P.M., Sinkey C.A., Browning R.L., Allaman M., Knapp H.R., Haynes W.G. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100(11):1161-1168. (Pubitemid 29426590)
7. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-376. (Pubitemid 11169009)
8. Félétou M., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: Where are we now? Arterioscler Thromb Vasc Biol. 2006;26(6):1215-1225. (Pubitemid 44305364)
9. Triggle C.R., Ding H. Endothelium-derived hyperpolarizing factor: Is there a novel chemical mediator? Clin Exp Pharmacol Physiol. 2002;29(3):153-160. (Pubitemid 34233968)
10. Köhler R., Hoyer J. The endothelium-derived hyperpolarizing factor: Insights from genetic animal models. Kidney Int. 2007;72(2):145-150. (Pubitemid 47067391)
11. Heil S.G., De Vriese A.S., Kluijtmans L.A., Mortier S., Den Heijer M., Blom H.J. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation. Cell Mol Biol (Noisy-le-grand). 2004;50(8):911-916.
12. Clarke Z.L., Moat S.J., Miller A.L., Randall M.D., Lewis M.J., Lang D. Differential effects of low and high dose folic acid on endothelial dysfunction in a murine model of mild hyperhomocysteinaemia. Eur J Pharmacol. 2006;551(1-3):92-97. (Pubitemid 44648062)
13. Taylor S.G., Weston A.H. Endothelium-derived hyperpolarizing factor: A new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci. 1988;9(8):272-274.
14. Brähler S., Kaistha A., Schmidt V.J., et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 2009;119(17):2323- 2332.
15. Wang L., Jhee K.H., Hua X., DiBello P.M., Jacobsen D.W., Kruger W.D. Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res. 2004;94(10):1318-1324. (Pubitemid 38724477)
16. Zhang D., Jiang X., Fang P., et al. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation. 2009;120(19):1893-1902.
17. Gupta S., Wang L., Hua X., Krijt J., Kozich V., Kruger W.D. Cystathionine beta-synthase p.S466L mutation causes hyperhomocysteinemia in mice. Hum Mutat. 2008;29(8):1048-1054.
18. Mervaala E.M., Teravainen T.L., Malmberg L., Laakso J., Vapaatalo H., Karppanen H. Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. Br J Pharmacol. 1997;121(3):503-510. (Pubitemid 27226303)
19. Brøndum E., Kold-Petersen H., Simonsen U., Aalkjaer C. NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Br J Pharmacol. 2010;159(1):154-165.
20. Zimny J., Sikora M., Guranowski A., Jakubowski H. Protective mechanisms against homocysteine toxicity: The role of bleomycin hydrolase. J Biol Chem. 2006;281(32):22485-22492.
21. Triggle C.R., Howarth A., Cheng Z.J., Ding H. Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): Does a dysfunctional endothelium contribute to the development of type 2 diabetes? Can J Physiol Pharmacol. 2005;83(8-9):681-700. (Pubitemid 41784008)
22. Dal-Ros S., Oswald-Mammosser M., Pestrikova T., et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology. 2010;138(4):1574-1584.
23. Moat S.J., McDowell I.F. Homocysteine and endothelial function in human studies. Semin Vasc Med. 2005;5(2):172-182. (Pubitemid 40944292)
24. Rodionov R.N., Dayoub H., Lynch C.M., et al. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res. 2010;106(3):551-558.
25. Waldron G.J., Ding H., Lovren F., Kubes P., Triggle C.R. Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. Br J Pharmacol. 1999;128(3):653-658. (Pubitemid 29504756)
26. Harrington L.S., Carrier M.J., Gallagher N., Gilroy D., Garland C.J., Mitchell J.A. Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol. 2007;293(3):H1682-H1688. (Pubitemid 47367215)
27. Matoba T., Shimokawa H., Nakashima M., et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106(12):1521-1530. (Pubitemid 32040953)
28. Adachi T., Weisbrod R.M., Pimentel D.R., et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med. 2004;10(11):1200-1207. (Pubitemid 39540436)
29. Sandow S.L., Neylon C.B., Chen M.X., Garland C.J. Spatial separation of endothelial small- and intermediate-conductance calcium-activated potassium channels (K(Ca)) and connexins: Possible relationship to vasodilator function? J Anat. 2006;209(5):689-698. (Pubitemid 44614697)
30. Feng J., Liu Y., Clements R.T., et al. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation. 2008;118(14 suppl):S46-S51.
31. Liu Y., Sellke E.W., Feng J., et al. Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass. Surgery. 2008;144(2):239-244. (Pubitemid 352024387)
32. Si H., Heyken W.T., Wolfle S.E., et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res. 2006;99(5):537-544. (Pubitemid 44337826)
33. Liu Y., Terata K., Chai Q., Li H., Kleinman L.H., Gutterman D.D. Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res. 2002;91(11):1070-1076. (Pubitemid 35416645)
34. Sesti F., Liu S., Cai S.Q. Oxidation of potassium channels by ROS: A general mechanism of aging and neurodegeneration? Trends Cell Biol. 2010;20(1):45-51.
35. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature. 2002;417(6888):515-522. (Pubitemid 34595912)
36. Shrivastava I.H., Bahar I. Common mechanism of pore opening shared by five different potassium channels. Biophys J. 2006;90(11):3929-3940. (Pubitemid 43846111)
37. Weatherall K.L., Goodchild S.J., Jane D.E., Marrion N.V. Small conductance calcium-activated potassium channels: From structure to function. Prog Neurobiol. 2010;91(3):242-255.
38. Dalsgaard T., Kroigaard C., Simonsen U. Calcium-activated potassium channels-a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther Targets. 2010;14(8):825-837.